Anti-CD69 autoantibodies cross-react with low density lipoprotein receptor-related protein 2 in systemic autoimmune diseases

Journal of Immunology

Volumn 166, Issue 2, 2001, Pages 1360-1369

  Yu, X ^a   Matsui, T ^a   Otsuka, M ^a   Sekine, T ^a   Yamamoto, K ^a   Nishioka, K ^a   Kato, T ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN;

AMINO ACID SEQUENCE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; BLOOD SAMPLING; COMPLEX FORMATION; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0035863868     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.2.1360     Document Type: Article

References (51)

1. Pathogenetic significance of antilymphocyte autoantibodies in systemic lupus erythematosus
2. A defect of immunoregulatory T cell subsets in systemic lupus erythematosus patients demonstrated with anti-2H4 antibody
3. Studies of immune functions of patients with systemic lupus erythematosus: T-cell subsets and antibodies to T-cell subsets
4. Antilymphocyte antibodies and systemic lupus erythematosus
5. Cell-type specificity of anti-CD45 autoantibodies in systemic lupus erythematosus
6. Autoantibodies specific for different isoforms of CD45 in systemic lupus erythematosus
7. Anti-β2 microglobulin lymphocytotoxic autoantibodies in systemic lupus erythematosus
8. Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases
9. The function of costimulatory molecules and the development of IL-4-producing T cells
10. CD69 in resting and activated T lymphocytes
11. T cell activation via leu-23 (CD69)
12. Expression and function of AIM, an activation inducer molecule of human lymphocytes, is dependent on the activation of protein kinase C
13. Functional and biochemical characterization of the activation CD69 antigen defined by A40 (MLR3) mAb
14. Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on activated human lymphocytes
15. Human T cell activation. III. Rapid induction of a phosphorylated 28 kD/32 kD disulfide-linked early activation antigen (EA 1) by 12tetradecanoyl phorbol-13-acetate, mitogens, and antigen
16. Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the leu-23 antigen
17. Functional characterization of an antigen involved in an early step of T-cell activation
18. Expression cloning of the early activation antigen CD69, a type II integral membrane protein with a C-type lectin domain
19. Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signaltransmitting receptors
20. Molecular characterization of the early activation antigen QD69: A type II membrane glycoprotein related to a family of natural killer cell activation antigen
21. Transcriptional regulation of the gene encoding the human C-type lectin leukocyte receptor AIM/CD69 and functional characterization of its tumor necrosis factor-α-responsive
22. Expression of the leukocyte early activation antigen CD69 is regulated by the transcription factor AP-1
23. Expression of the early lymphocyte activation antigen CD69, a C-type lectin, is regulared by mRNA degradation associated with Au-rich sequence motifs
24. Activation-induced apoptosis in lymphocytes
25. Activation of naive, memory and effector cells
26. Characterization and regulation of CD69 expression on rheumatoid arthritis synovial fluid T cells
27. The CD69 activation pathway in rheumatoid arthritis synovial fluid T cells
28. CD69 on synovial T cells in rheumatoid arthritis correlates with disease activity
29. Participation of the CD69 antigen in the T-cell activation press of patients with systemic lupus erythematosus
30. CD69 to CD3 ratio of peripheral blood mononuclear cells as a marker to monitor systemic lupus erythematosus disease activity
31. CD69 expression reliably predicts the anti-CD3 induced proliferative response of lymphocytes from human immunodeficiency vires type 1-infected patients
32. Autoimmune target in Heymann nephritis is a glycoprotein with homology to the LDL receptor
33. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
34. The 1982 revised criteria for the classification of systemic lupus erythematosus
35. Criteria for diagnosis of Behcet's disease
36. A vector to express and purify foreign proteins in Escherichia coli by fusion to and separation from, maltose binding protein
37. Isolation and characterization of a complementary DNA expressing human U1 small nuclear ribonucleoprotein C polypeptide
38. Antinuclear antibodies (ANA): Diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity
39. Induction of autoreactive B cells allows priming of autoreactive T cells
40. Molecular mimicry and autoimmune disease
41. Triggering of human monocyte activation through CD69, a member of the natural killer cell gene complex family of signal transducing receptors
42. Preferential involvement of a phospholipase A2-dependent pathway in CD69-mediated platelet activation
43. Tumor necrosis factor-α production induced in T lymphocytes through the AIM/CD69 activation pathway
44. Transcriptional regulation of interleukin-2 gene expression by CD69-generated signals
45. The CD69 receptor: A multipurpose cell-surface trigger for hematopoietic cells
46. Rheumatoid factors
47. Analysis of glomeruli-eluted gp330 autoantibodies and of gp330 antigen of Heymann nephritis
48. Low density lipoprotein receptor-related protein and gp 330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance
49. Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes
50. Pathogenic antibodies inhibit the binding of apolipoproteins to Megalin/gp330 in passive Heyman nephritis
51. Serum antibodies against Megalin (GP330) in patients with autoimmune thyroiditis